Working with TipRanks
Follow Us
Stock Ideas
Daily Updates
Calendars
Education
About Us
Working with TipRanks
Follow Us
Coherus Biosciences (CHRS)
NASDAQ:CHRS
Coherus Biosciences (CHRS) Stock Price & Analysis
654 Followers
CHRS Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$3.60 - $14.11
Previous Close$4.45
Volume4.42M
Average Volume (3M)1.84M
Market Cap
$358.46M
Enterprise Value$456.28M
Total Cash (Recent Filing)$128.09M
Total Debt (Recent Filing)$225.90M
Price to Earnings (P/E)-1.3
Beta1.35
Next Earnings
Aug 03, 2023EPS Estimate
-$0.72Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.47
Shares Outstanding80,553,730
10 Day Avg. Volume3,456,599
30 Day Avg. Volume1,843,704
Standard Deviation0.17
R-Squared0.09
Alpha-0.02
Financial Highlights & Ratios
Price to Book (P/B)-1.63
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-1.20
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue3.02
Enterprise Value/Gross Profit-6.51
Enterprise Value/Ebitda-1.95
Forecast
1Y Price Target
$14.94Price Target Upside235.73% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
Coherus Biosciences News
Press ReleasesCoherus Announces U.S. Launch of UDENYCA® Autoinjector
Press ReleasesCoherus Prices Public Offering of Common Stock
Stock Analysis & Ideas3 Best Stocks to Buy Now, 5/9/2023, According to Top Analysts
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Product Insights
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
CHRS FAQ
What was Coherus Biosciences’s price range in the past 12 months?
Coherus Biosciences lowest stock price was $3.60 and its highest was $14.11 in the past 12 months.
What is Coherus Biosciences’s market cap?
Currently, no data Available
When is Coherus Biosciences’s upcoming earnings report date?
Coherus Biosciences’s upcoming earnings report date is Aug 03, 2023 which is in 59 days.
How were Coherus Biosciences’s earnings last quarter?
Coherus Biosciences released its earnings results on May 08, 2023. The company reported -$0.96 earnings per share for the quarter, missing the consensus estimate of -$0.721 by -$0.239.
Is Coherus Biosciences overvalued?
According to Wall Street analysts Coherus Biosciences’s price is currently Undervalued.
Does Coherus Biosciences pay dividends?
Coherus Biosciences does not currently pay dividends.
What is Coherus Biosciences’s EPS estimate?
Coherus Biosciences’s EPS estimate is -$0.72.
How many shares outstanding does Coherus Biosciences have?
Coherus Biosciences has 80,553,730 shares outstanding.
What happened to Coherus Biosciences’s price movement after its last earnings report?
Coherus Biosciences reported an EPS of -$0.96 in its last earnings report, missing expectations of -$0.721. Following the earnings report the stock price went down -27.396%.
Which hedge fund is a major shareholder of Coherus Biosciences?
Among the largest hedge funds holding Coherus Biosciences’s share is Platinum Investment Management. It holds Coherus Biosciences’s shares valued at 4M.
---
Coherus Biosciences Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$14.94 (235.73% Upside)
$14.94 (235.73% Upside)
Blogger Sentiment
Bullish
CHRS Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 112.2K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 18.7%
Last 30 Days ▲ 49.8%
Last 30 Days ▲ 49.8%
News Sentiment
Very Negative
Bullish news 0%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-40.34%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-32.18%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Coherus Biosciences
Coherus BioSciences, Inc. is a commercial-stage clinical biologics platform company, which engages in the development and commercialization of biosimilar therapeutics. Its clinical products include pegfilgrastim biosimilar, adalimumab biosimilar, etanercept biosimilar, ranibizumab biosimilar, and aflibercept biosimilar. The company was founded by Dennis M. Lanfear, Stuart E. Builder, Dr. Alan Herman, Doug Farrar and Steve Glover in September 2010 and is headquartered in Redwood City, CA.
---
Top 5 ETFs holding CHRS
Vanguard Health Care ETF
$1.60M
iShares Core S&P Total U.S. Stock Market ETF
$547.26K
Middlefield Healthcare Dividend ETF Registered
$321.94K
Fidelity MSCI Health Care Index ETF
$177.54K
iShares NASDAQ US Biotechnology UCITS ETF
$157.91K
Up to five ETFs with an Outperform Smart Score that hold CHRS. The ETFs are listed according to market value of CHRS within the ETF
---
---